title: [Effects of jiawei huzhang san decoction on the expressions of inflammatory factors MCP-1 and PDGF-BB in rat models of experimental autoimmune prostatitis].
abstract: OBJECTIVE
  To study the effects of Jiawei Huzhang San (JWHZS) decoction on the expressions of the inflammatory factors monocyte chemoattractant protein-1 (MCP-1) and platelet-derived growth factor-BB (PDGF-BB) on experimental autoimmune prostatitis in rats.
  
  
  METHODS
  Twelve male Wistar rats were taken as normal controls, and models of experimental autoimmune prostatitis were established in another 60 by injection of SC purified prostate protein with FCA, and then divided into five groups to be treated with normal saline, indomethacin, high-dose JWHZS (0.445 g/kg), medium-dose JWHZS (0.223 g/kg) and low-dose JWHZS (0.089 g/kg), respectively. All the rats were sacrificed at 30 days after the treatment for detection of the mRNA and protein expressions of inflammatory factors by immunohistochemistry and fluorescent quantitative RT-PCR.
  
  
  RESULTS
  In the high-, medium- and low-dose JWHZS groups, the mRNA expressions of MCP-1 (0.31 +/- 0.14, 0.49 +/- 0.21 and 0.62 +/- 0.28) and PDGF-BB (0.50 +/- 0.22, 0.54 +/- 0.17 and 0.71 +/- 0.29), and the protein expressions of MCP-1 (677 +/- 208, 725 +/- 311 and 1302 +/- 884) and PDGF-BB (1265 +/- 698, 1347 +/- 827 and 1655 +/- 812) were significantly lower than in the model control group (MCP-1 mRNA: 1.12 +/- 0.43; MCP-1 protein: 2201 +/- 934; PDGF-BB mRNA: 1.14 +/- 0.51; PDGF-BB protein: 2754 +/- 852) (P < 0.05). And JWHZS exhibited a significantly better activity at high and medium doses than at a low dose (P < 0.05). In the indomethacin control group, both the mRNA and protein expressions of MCP-1 (0.71 +/- 0.34 and 1824 +/- 1157) and PDGF-BB (1.08 +/- 0.37 and 2493 +/- 924) were markedly higher than in the JWHZS groups (P < 0.01).
  
  
  CONCLUSIONS
  Down-regulation of the inflammatory factors MCP-1 and PDGF-BB may be the important molecular mechanism of JWHZS acting on experimental autoimmune prostatitis.
authors.affiliation: Department of Surgery, The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China. supergoon@163.com
authors.forename: Qing
authors.initials: Q
authors.lastname: Zhou
authors.forename: Xue-fei
authors.initials: XF
authors.lastname: Tian
authors.forename: Xiu-ying
authors.initials: XY
authors.lastname: Gong
authors.forename: Ya-lan
authors.initials: YL
authors.lastname: Feng
authors.forename: Hua
authors.initials: H
authors.lastname: Hu
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000378:metabolism; D000077214:Becaplermin; D018932:Chemokine CCL2 / Q000378:metabolism*; D004195:Disease Models, Animal; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D007249:Inflammation; D008297:Male; D008517:Phytotherapy; D010982:Platelet-Derived Growth Factor / Q000378:metabolism*; D011472:Prostatitis / Q000188:drug therapy* / Q000378:metabolism; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D017208:Rats, Wistar
chemical_list: C491766:Ccl2 protein, rat; D018932:Chemokine CCL2; D004365:Drugs, Chinese Herbal; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D000077214:Becaplermin